A tubo-ovarian abscess (TOA) is not cancer. It is an infection, specifically a pus-filled inflammatory mass involving the fallopian tubes and ovaries, almost always caused by bacteria. However, ovarian cancer can sometimes look remarkably similar to a TOA on imaging, and in certain populations, particularly postmenopausal women, a mass initially diagnosed as an abscess turns out to be malignant surprisingly often. So while the two conditions are fundamentally different, the overlap in how they appear is a real clinical concern.
What a TOA Actually Is
A tubo-ovarian abscess develops as a severe complication of pelvic inflammatory disease (PID). It starts when a lower genital tract infection, often involving bacteria like E. coli, Bacteroides, or sexually transmitted organisms, travels upward into the fallopian tubes and ovaries. The resulting infection creates an inflamed, pus-filled mass. In some cases, the infection spreads from a neighboring organ like the appendix rather than from the reproductive tract itself.
The classic symptoms are abdominal pain, fever, a pelvic mass that a doctor can feel on exam, and elevated white blood cell counts. Some women also notice foul-smelling vaginal discharge. TOAs most commonly affect sexually active women of reproductive age, but they can also occur after menopause, where the picture gets more complicated.
Why TOA and Ovarian Cancer Look Alike
Both a TOA and ovarian cancer can show up as a complex pelvic mass on ultrasound or CT, with a mix of solid and fluid-filled areas. This visual overlap is what makes the question “could this be cancer?” so reasonable. On standard imaging alone, it can be genuinely difficult to tell the two apart.
MRI does a better job of distinguishing them. TOAs tend to be smaller (averaging about 7 cm versus nearly 11 cm for ovarian cancers), more likely to have blurry margins that blend into surrounding tissue, and more often associated with dilated fallopian tubes (about 68% of the time compared to 14% for malignancies). The fluid inside an abscess behaves differently on specialized MRI sequences: pus restricts the movement of water molecules in a way that normal cyst fluid in a tumor does not. After contrast dye is injected, the pus inside an abscess shows no enhancement, while the solid portions of a cancerous tumor light up.
Still, nearly half of TOAs that contain both solid and cystic areas can mimic the MRI appearance of cancer in their solid portions, creating what radiologists call a “pseudotumor area.” This is one reason imaging alone doesn’t always settle the question.
The CA-125 Problem
CA-125 is a blood protein commonly used as a marker for ovarian cancer. The trouble is that it rises in response to any condition that irritates the lining of the abdominal cavity, and a TOA does exactly that. One well-documented case of a TOA in a reproductive-age woman produced a CA-125 level of 1,160 U/mL, a value that would strongly suggest malignancy in most clinical contexts. That case turned out to be entirely benign, and the CA-125 returned to normal after the infection resolved.
This means an elevated CA-125 in the setting of a pelvic mass cannot reliably distinguish between an abscess and cancer. It’s one more reason the two conditions are so easily confused.
Age Changes the Risk Dramatically
For premenopausal women, the chance that a TOA is hiding an underlying cancer is very low, around 1.3% in one study of 76 patients. The vast majority of TOAs in younger women are exactly what they appear to be: infections that respond to antibiotics or drainage.
For postmenopausal women, the picture is starkly different. In the same study, 47% of postmenopausal women diagnosed with a TOA turned out to have a concurrent gynecological malignancy. That’s nearly half. The cancers found included a variety of types, not just ovarian. Postmenopausal women with TOAs were also less likely to have the “typical” infection symptoms: only 41% had a significant fever compared to 74% of premenopausal women, and they were more likely to have irregular vaginal bleeding and fluid buildup in the abdomen (ascites), both of which are red flags for malignancy.
The reason for this pattern is straightforward. TOAs are primarily an infection of the reproductive tract, and the risk factors that drive them (sexual activity, untreated STIs) are far more common before menopause. When a postmenopausal woman develops what looks like a TOA, the underlying cause is more likely to be a tumor that has become secondarily infected or has created conditions that mimic an abscess. The research is blunt about this: conservative treatment of a TOA has no place during menopause, and the default approach should be to rule out cancer.
What Happens When Antibiotics Don’t Work
Most genuine TOAs respond to intravenous antibiotics within a few days. When they don’t, it raises suspicion. In one reported case, a pelvic mass showed no change in size after six days of IV antibiotics, and the patient’s fever persisted. That mass was ultimately found to be malignant rather than infectious.
A mass that fails to shrink with appropriate antibiotic therapy is one of the clearest signals that something other than infection may be going on. This is especially true if the patient lacks the typical infection pattern (high fever, elevated white blood cells, a clear history of PID or STI exposure).
Follow-Up Imaging and Resolution
After a TOA is treated, follow-up imaging confirms whether the mass has fully resolved. Research suggests scheduling a follow-up ultrasound roughly 60 to 70 days after the initial diagnosis. Masses that resolve completely on this timeline are reassuring. A mass that persists, grows, or develops new solid components warrants further investigation, potentially including surgical exploration and tissue sampling to rule out malignancy.
For premenopausal women with a straightforward presentation (fever, pain, known infection risk, response to antibiotics), the follow-up scan is often a formality. For postmenopausal women, or for anyone whose mass doesn’t behave the way an abscess should, that follow-up imaging is critical. In these cases, tissue diagnosis through biopsy or surgery may be the only way to definitively answer the question.